{
    "clinical_study": {
        "@rank": "127939", 
        "arm_group": {
            "arm_group_label": "LIFUP", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "We intend to use focused ultrasound to stimulate or suppress brain activity in patients with\n      epilepsy. We hypothesize that focused ultrasound is capable of brain stimulation or\n      suppression visible with functional MRI, and will not cause tissue damage."
        }, 
        "brief_title": "Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy", 
        "condition": "Epilepsy, Temporal Lobe", 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Epilepsy, Temporal Lobe"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with clinical evidence from their diagnostic evaluations of unilateral\n             hippocampal dysfunction and epileptogenicity.\n\n          -  Subjects with seizures that have been refractory to treatment with at least three\n             currently marketed antiepileptic drugs.\n\n          -  Subjects with epilepsy who would clearly benefit from surgical intervention.\n\n          -  Subjects who have been offered a non-dominant anterior-mesial temporal lobe resection\n             as treatment for medication refractory epilepsy.\n\n        Exclusion Criteria:\n\n          -  Subjects with a cognitive or psychiatric disorder that limits the ability to give\n             informed consent or are unable to cooperate with the testing.\n\n          -  Subjects with dementia, delirium and psychotic symptoms. - Subjects with\n             ferromagnetic materials in the head.\n\n          -  Subjects with severe cardiac disease, increased intracranial pressure, or a TENS\n             unit.\n\n          -  Subjects who exhibit primary generalized seizures or pseudoseizures.\n\n          -  Subjects who have seizures secondary to drugs, alcohol, metabolic illness or\n             progressive degenerative disease.\n\n          -  Subjects who have experienced status epilepticus during the 3-week baseline period\n             prior to the operation.\n\n          -  Subjects (females) who are pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151175", 
            "org_study_id": "BX001"
        }, 
        "intervention": {
            "arm_group_label": "LIFUP", 
            "intervention_name": "LIFUP", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "alexkorb@yahoo.com", 
                "last_name": "Alex Korb, PhD", 
                "phone": "310-985-0867"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "UCLA"
            }, 
            "investigator": {
                "last_name": "John Stern, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "LIFUP for Treatment of Temporal Lobe Epilepsy", 
        "other_outcome": [
            {
                "measure": "Change in BOLD signal", 
                "safety_issue": "No", 
                "time_frame": "Same day"
            }, 
            {
                "measure": "Change in epileptiform discharges", 
                "safety_issue": "No", 
                "time_frame": "Same day"
            }, 
            {
                "measure": "Change in epileptiform discharge %", 
                "safety_issue": "No", 
                "time_frame": "Same day"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absence of histological changes", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Brief Symptom Inventory changes", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Beck Depression Inventory changes", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Neuropsychiatric changes", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Neurological changes", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Seizure frequency changes", 
                "safety_issue": "Yes", 
                "time_frame": "6 days"
            }
        ], 
        "source": "BrainSonix Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Gerald J & Dorothy R Friedman NY Foundation For Medical Research", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of California, Los Angeles", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "BrainSonix Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}